High unmet need InMed focuses on proprietary small molecule drug candidates targeting CB1/CB2 receptors with programs in Alzheimer’s, ocular, and dermatological indications, signaling opportunities to engage with specialty pharma and clinics addressing neurodegenerative and eye/skin diseases.

Cannabinoid platform With BayMedica as a subsidiary and leadership in rare cannabinoids and their small molecule analogs, there is a potential cross-sell path for cannabinoid-based research tools, formulation collaborations, and regulatory advisory services to researchers and biotech partners.

Board and funding activity Recent board appointments and planned financing indicate ongoing governance refinement and capital readiness, suggesting readiness for strategic partnerships, licensing deals, or co-development opportunities with investors and larger biotech entities.

Clinical and preclinical focus Preclinical data and participation in major conferences (AAIC) highlight a push toward advancing pipelines; target opportunities include CRO partnerships, translational research collaborations, and early-access programs with neuroscience and ophthalmology ecosystems.

Modest revenue scale With revenue in the low single digits and ~11-50 employees, InMed presents high-growth partnership potential for larger pharma seeking niche cannabinoid programs, toll manufacturing, or in-licensing arrangements to expand their pipeline portfolio.